Literature DB >> 11726727

Are moderate degrees of hyperbilirubinemia in healthy term neonates really safe for the brain?

I Soorani-Lunsing1, H A Woltil, M Hadders-Algra.   

Abstract

In 1994 the American Academy of Pediatrics recommended more liberal rules for the treatment of hyperbilirubinemia in healthy term newborns. Yet, the safety of moderate degrees of hyperbilirubinemia in healthy term newborns is debated. To evaluate the safety of moderate degrees of hyperbilirubinemia, we assessed neurologic condition of 20 healthy nonhemolytic term newborns with peak total serum bilirubin levels of 233-444 micromol/L and 20 control infants matched for sex and gestational age at birth. Neurologic condition was evaluated with techniques focusing on the presence of minor neurologic dysfunction: in the newborn period according to Prechtl, at 3 mo on the basis of the quality of general movements, and at 12 mo according to Touwen. Moderate hyperbilirubinemia turned out to be associated with a significant increase in minor neurologic dysfunction throughout the first year of life. At 12 mo a strong dose-response relationship between the degree of hyperbilirubinemia and the severity of minor neurologic dysfunction was present. Our results indicate that total serum bilirubin levels 335 micromol/L should be avoided.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11726727     DOI: 10.1203/00006450-200112000-00012

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  13 in total

Review 1.  Newborn jaundice and kernicterus--health and societal perspectives.

Authors:  Vinod K Bhutani; Lois H Johnson
Journal:  Indian J Pediatr       Date:  2003-05       Impact factor: 1.967

2.  Is the hour-specific bilirubin nomogram suitable for predicting hyperbilirubinemia.

Authors:  Bilgen Hülya; Ozek Eren; Topuzoglu Ahmet
Journal:  Indian J Pediatr       Date:  2008-05       Impact factor: 1.967

3.  Serum bilirubin level to cause encephalopathy remains elusive?

Authors:  Pankaj Garg; Rajeev Krishak
Journal:  Indian J Pediatr       Date:  2005-01       Impact factor: 1.967

4.  Visuocortical function in infants with a history of neonatal jaundice.

Authors:  Chuan Hou; Anthony M Norcia; Ashima Madan; William V Good
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-02       Impact factor: 4.799

Review 5.  Movement disorders due to bilirubin toxicity.

Authors:  Jessica Rose; Rachel Vassar
Journal:  Semin Fetal Neonatal Med       Date:  2014-12-16       Impact factor: 3.926

6.  Maternal Body Mass Index in Early Pregnancy and Risk of Epilepsy in Offspring.

Authors:  Neda Razaz; Kristina Tedroff; Eduardo Villamor; Sven Cnattingius
Journal:  JAMA Neurol       Date:  2017-06-01       Impact factor: 18.302

7.  Induction of bilirubin clearance by the constitutive androstane receptor (CAR).

Authors:  Wendong Huang; Jun Zhang; Steven S Chua; Mohammed Qatanani; Yunqing Han; Riccarda Granata; David D Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

8.  Bilirubin as a determinant for altered neurogenesis, neuritogenesis, and synaptogenesis.

Authors:  Adelaide Fernandes; Ana Sofia Falcão; Elsa Abranches; Evguenia Bekman; Domingos Henrique; Lorene M Lanier; Dora Brites
Journal:  Dev Neurobiol       Date:  2009-08       Impact factor: 3.964

9.  Genetic Analysis of UGT1A1 Polymorphisms Using Preserved Dried Umbilical Cord for Assessing the Potential of Neonatal Jaundice as a Risk Factor for Autism Spectrum Disorder in Children.

Authors:  Tomoko Horinouchi; Kaori Maeyama; Masashi Nagai; Masami Mizobuchi; Yasuko Takagi; Yuka Okada; Takeshi Kato; Mio Nishimura; Yoko Kawasaki; Mieko Yoshioka; Satoshi Takada; Hisayuki Matsumoto; Yuji Nakamachi; Jun Saegusa; Sachiyo Fukushima; Kazumichi Fujioka; Kazumi Tomioka; Hiroaki Nagase; Kandai Nozu; Kazumoto Iijima; Noriyuki Nishimura
Journal:  J Autism Dev Disord       Date:  2021-03-17

10.  The effect of hyperbilirubinemia on motor repertoire of infants between 3 and 5 months of age.

Authors:  Aysu Kahraman; Halil Alkan; Hasan Tolga Çelik; Akmer Mutlu
Journal:  Eur J Pediatr       Date:  2021-07-02       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.